KSBB Journal

The Korean Society for Biotechnology and Bioengineering (한국생물공학회)
권호 표지

Preparation and Immunogenicity of the Combined Vaccine Composed of the Polysaccharide Capsule of Samonella typhi and Japanese Encephalitis Virus

장티푸스 협막 다당체와 일본 뇌염 바이러스의 혼합 백신 제조 및 면역성

  • Published : 2004.02.01
Download PDF
⟨ Previous Next ⟩

Abstract

The immunogenicity of investigational combined vaccine, composed of the Japanese encephalis virus(JEV) and the polysaccharide capsule(Vi) of Salmonella typhi covalently bound to tetanus toxoid(TT) was evaluated in mice. The mice immunized with combined vaccine elicited higher anti-Vi Immunoglobulin G(IgG) as well as anti-JEV IgG levels than the mice immunized with Vi-TT or JEV alone. The combined vaccine produced four-fold increase in anti-Vi IgG level than Vi-TT alone. In JEV the combined vaccine was significantly more immunogenic than JEV alone and induced six-fold increase in IgG level. Adsorption of combined vaccine onto aluminium hydroxide gel also enhanced IgG level for both Vi and JEV.

장티푸스 협막 다당체와 일본 뇌염 바이러스로 구성되어있는 혼합백신을 제조하여 마우스에서 면역성을 측정하였다. 혼합 항원 백신은 단일 항원을 투여한 경우보다 장티푸스와 일본 뇌염에 대해서 더 높은 IgG 항체 형성을 나타내었다. Aluminium hydroxide를 adjuvant로 첨가한 경우에도 첨가하지 않은 대조군에 비하며 모두 IgG 항체 형성이 증가하는 것으로 나타났다. 일본뇌염의 경우 중화항체 값 측정 시험에서도 혼합 항원백신은 일본뇌염 단독 항원 시에 비교해서 더 많은 중화항체 값을 형성하는 결과를 나타내었다. 본 실험에서 장티푸스 협막 다당체와 일본뇌염 바이러스의 혼합백신은 서로 다른 성분의 항원간에 나타날 수 있는 항체 형성에 대한 masking effect가 발생하지 않으며 오히려 synergic effect를 나타낸다는 사실을 보여주었다. 본 연구에서는 접종시기가 유사한 두 항원의 혼합 백신으로의 사용가능성을 높여주고 최근에 백신 산업에서 종류가 다른 여러 백신들을 혼합하여 다가백신을 제조 생산하는 추세의 산업화에 큰 기대효과를 제공할 수 있으리라 사려된다.

Keywords

References

  1. Bull. WHO v.63 Current Japanese Encephalitis: Current Worldwide Stantus Umenai,I.
  2. J. Gen. Virol. v.76 Nucleotide and amino acid sequences of the structural protein genes of Japanese encephalitis virus from different geographical locations Ni,H.;A.D.T.Barett https://doi.org/10.1099/0022-1317-76-2-401
  3. Rev. Infect. Dis. v.8 Summary of an international workshopon typhoid fever Edelman,R.;Levine,M.M. https://doi.org/10.1093/clinids/8.3.329
  4. Bioassay v.9 Research opportunities in typhoid fever, Epidemiology and molecular biology Calva,E.;J.L.Puente;J.J.Calva https://doi.org/10.1002/bies.950090509
  5. Arch. Intern. Med. v.155 A new typhoid vaccine composed of the Vi capsular polysaccharide Plotkin,S.A.;N.Bouverest-Le Cam https://doi.org/10.1001/archinte.155.21.2293
  6. Vaccine v.12 Clinical and serological responses following primary and booster immunization with Salmonella typhi Vi capsular polysaccharide vaccine Keitel,W.A.;N.L.Bond;J.M.Zahrdanik;T.A.Cramoton;J.B.Robbins https://doi.org/10.1016/0264-410X(94)90194-5
  7. Pediatr Infect. Dis. J. v.10 Efficacy in infancy of oligosaccharide conjugate Haemophilus influenzae type b vaccine in a United states population of 61,080 children Black,S.B.;H.R.Shinefield;B.Fireman;R.Hiatt;M.Polen;E.Vittinghoff https://doi.org/10.1097/00006454-199102000-00004
  8. Lancet v.344 Efficacy of Haemophilus influenzae type b conjugate vaccine PRP-T Booy,R.;S.Hodgson;L.Carpenter;R.T.M.White;M.P.Slack;J.A.MacFarlane;E.A.Haworth;M.Kiddle;S.Shribman;J.S.Roberts https://doi.org/10.1016/S0140-6736(94)91400-1
  9. Infect. Immun. v.59 Preparation, characterization and immunogenicity of conjugates composed of the O-specific polysaccharide of Shigella dysenteriae type Ⅰ bound to tetanus toxoid Chu,C.Y.;B.Liu;D.Watson;S.C.Szu;D.Bryla;J.Shiloach;R.Schneerson;J.Robbins
  10. J. Bacteriol. v.43 Growth requirement of the meningococcus Frantz,I.D.
  11. J. Biol. Chem. v.180 The reaction of acetylcholine and other carboxylic acid derivatives with hydroxylamine, and its analytical application Hestrin,S.
  12. J. Biol. Chem. v.193 Protein measurement with the Follin-Phenol reagents Lowry,O.H.;N.J.Rosebrough;A.L.Farr;R.J.Randall
  13. J. Exp. Med. v.166 Vi capsular polysaccharide-pretein conjugates for prevention of typhoid fever Szu,S.C.;A.L.Stone;J.D.Robbins;R.Schneerson;J.Robbins https://doi.org/10.1084/jem.166.5.1510